10231 - Familial Hypercholesterolemia and High Lipoprotein(a): A Dual Threat

Course Directors

Rob M. Greenfield, M.D., University of California Irvine
Patrick M. Moriarty, M.D., University of Kansas Medical Center
Nathan D. Wong, Ph.D., University of California Irvine

Description

Familial hypercholesterolemia (FH) is a autosomal dominant condition characterized by very high LDL-cholesterol levels from birth and premature atherosclerotic cardiovascular disease (ASCVD). With a prevalence of approximately 1 in 200-300 in its heterozygous form, FH is among the most common of genetic diseases, however, fewer than 5% of patients are aware of their condition and appropriately diagnosed. Elevated lipoprotein(a) levels is another familial hyperlipidemia and is associated with excess risk of ASCVD independent of LDL-C. While statins and other newer therapies have dramatically improved the outcomes for persons with FH, there are no currently available therapies (although several are in development) for elevated lipoprotein(a), with the exception of lipoprotein apheresis. This program will review the evaluation and treatment of both FH and elevated lipoprotein(a) and currently available therapeutic options.

Credits

AMA PRA Category 1 Credits™

Opus Medicus designates this Internet enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Maintenance of Certification (MOC) Credits

In addition to AMA PRA Category 1 Credits™, Opus Medicus designates this course for Specialty Board MOC Program Credits:

1.0 ABIM MOC Points1

Accreditation Statement

Opus Medicus is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Tuition Fees

Course & Credits: Free

Course Dates

Offered Date: 17-Nov-2020
Expiration Date: 17-Nov-2023

Objectives

After taking this course, participants will have an understanding of:

1. Screening and assessment of familial hypercholesterolemia (FH) and elevated lipoprotein(a) and their cardiovascular consequences.

2. Methods to improve the accuracy of identification of persons with these conditions.

3. Current treatment strategies and guidelines for treatment of persons with FH and elevated lipoprotein(a).

Topics

1. Epidemiology and cardiovascular consequences of persons with FH and elevated lipoprotein(a).

2. Methods for screening and identification of persons with FH and elevated lipoprotein(a).

3. Current treatment strategies for persons with FH and elevated lipoprotein(a).

The course also discusses dyslipidemia familial hypercholesterolemia low density lipoprotein-cholesterol lipoprotein(a) atherosclerotic cardiovascular disease.

American Board of Medical Specialties (ABMS) / Accreditation Council for Graduate Medical Education (ACGME) Competencies

☑  Patient Care (PC)
☑  Medical Knowledge (MK)

Financial Relationship Disclosure and Content Attestation

Dr. Rob Greenfield, course director, discloses that he has consulted for Amgen and Sanofi-Regeneron. He attests that neither of these entities has had an influence on the course content. Dr. Patrick Moriarty, course director, discloses that he has received research grants from Regeneron, Sanofi, Amgen, and Novartis and has consulted for Kaneka, Pfizer, Esperion, and Amarin. He attests that none of these entities have had an influence on the course content. Dr. Nathan Wong, course director and moderator, discloses that he has received research grants from Amarin, Amgen, and Novartis, and lectured for Esperion and Amarin. He attests that none of these entities have had an influence on the course content. Dr. Paul VanderLaan, reviewer, discloses that he has consulted in an advisory capacity for Gala Therapeutics, Caris Life Sciences, Foundation Medicine, Flatiron Health, Intuitive Surgical, and Clearview Healthcare Partners. He attests that none of these entities have had an influence on the course content or his review thereof. Dr. Steven R. Tahan, Education Committee Chair, attests that commercial entities with which he has relationships do not offer healthcare-related products or services relevant to the content of this course. No other person who has provided content for or who can influence the content of this course has disclosed financial relationships with commercial entities that offer healthcare-related products or services relevant to the course content. Financial support for this course has been received from Kaneka Pharma America, LLC, which has had no influence on the course content.

Supported Computer Hardware and Software Configurations2

Supported client computing platforms include:

A broadband Internet connection is required (e.g., cable, DSL, and 3G or 4G wireless). The course presentation is automatically scaled to the size of the display, from 800x480 pixels (minimum supported) to 1920x1200 pixels. On some smart phones, viewing courses may be tedious.

Supported browsers include:

Javascript, cookies, and popups must be enabled on your browser (which is the default configuration for most browsers).


1. Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points for the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) Program, in addition to AMA PRA Category 1 Credits™. Participants will earn MOC points equivalent to the amount of AMA PRA Category 1 credits claimed for the activity. Immediately upon course completion, Opus Medicus will submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

2. The course may also be viewable on other client computing platforms that comply with Internet standards. If you experience technical problems that prevent you from viewing the course, we will promptly issue a full refund upon request.